Trails Edge Capital Partners
Latest statistics and disclosures from Trails Edge Capital Partners's latest quarterly 13F-HR filing:
- Top 5 stock holdings are LBRX, NRIX, IMCR, TRAX, FDMT, and represent 28.81% of Trails Edge Capital Partners's stock portfolio.
- Added to shares of these 10 stocks: TRAX (+$31M), BMRN (+$29M), INSM (+$25M), Kailera Therapeutics (+$22M), INCY (+$18M), DSGN (+$17M), AVTX (+$17M), MLTX (+$15M), FDMT (+$12M), IMCR (+$12M).
- Started 13 new stock positions in IMA, INSM, FBRX, TRAX, Kailera Therapeutics, MLTX, ALT, INCY, AVTX, Research Alliance Corp Iii. BMRN, AURA, OKUR.
- Reduced shares in these 10 stocks: PCVX (-$39M), DFTX (-$33M), RVMD (-$24M), RCUS (-$23M), MIRM (-$13M), XENE (-$12M), IMVT (-$10M), NRIX, NGNE, VTVT.
- Sold out of its positions in RCUS, DFTX, IMVT, PCVX.
- Trails Edge Capital Partners was a net buyer of stock by $115M.
- Trails Edge Capital Partners has $630M in assets under management (AUM), dropping by 44.30%.
- Central Index Key (CIK): 0002077247
Tip: Access up to 7 years of quarterly data
Positions held by Trails Edge Capital Partners consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Trails Edge Capital Partners
Trails Edge Capital Partners holds 35 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Lb Pharmaceuticals Com Shs (LBRX) | 7.8 | $49M | +15% | 1.5M | 32.45 |
|
| Nurix Therapeutics (NRIX) | 6.1 | $38M | -9% | 1.6M | 24.26 |
|
| Immunocore Hldgs Ads (IMCR) | 5.4 | $34M | +55% | 1.1M | 31.75 |
|
| First Tracks Biotherapeutics Ord Shs (TRAX) | 4.8 | $31M | NEW | 1.5M | 20.12 |
|
| 4d Molecular Therapeutics In (FDMT) | 4.7 | $30M | +70% | 2.2M | 13.30 |
|
| BioMarin Pharmaceutical (BMRN) | 4.7 | $29M | NEW | 512k | 57.22 |
|
| Design Therapeutics (DSGN) | 4.6 | $29M | +134% | 2.0M | 14.47 |
|
| Xenon Pharmaceuticals (XENE) | 4.2 | $27M | -31% | 440k | 60.36 |
|
| Mirum Pharmaceuticals (MIRM) | 4.2 | $26M | -33% | 223k | 117.07 |
|
| Insmed Com Par $.01 (INSM) | 3.9 | $25M | NEW | 230k | 106.62 |
|
| Cytokinetics Com New (CYTK) | 3.9 | $25M | -3% | 288k | 85.19 |
|
| Syndax Pharmaceuticals (SNDX) | 3.9 | $24M | +58% | 1.1M | 21.86 |
|
| Neurogene (NGNE) | 3.6 | $23M | -8% | 715k | 31.45 |
|
| Kailera Therapeutics Common Stock | 3.4 | $22M | NEW | 985k | 22.03 |
|
| Revolution Medicines (RVMD) | 3.4 | $22M | -52% | 116k | 187.28 |
|
| Inhibikase Therapeutics Com New (IKT) | 2.9 | $18M | +12% | 9.1M | 2.03 |
|
| Incyte Corporation (INCY) | 2.8 | $18M | NEW | 155k | 113.36 |
|
| Avalo Therapeutics Com New (AVTX) | 2.6 | $17M | NEW | 892k | 18.48 |
|
| Moonlake Immunotherapeutics Class A Ord (MLTX) | 2.3 | $15M | NEW | 750k | 19.47 |
|
| Faeth Therapeutics Com New (FTH) | 2.0 | $13M | +312% | 515k | 25.00 |
|
| X4 Pharmaceuticals Com New (XFOR) | 1.9 | $12M | 2.6M | 4.67 |
|
|
| Ocuphire Pharma (IRD) | 1.8 | $11M | +448% | 2.7M | 4.11 |
|
| Sol-gel Technologies Shs New (SLGL) | 1.6 | $10M | +63% | 139k | 74.14 |
|
| Aura Biosciences (AURA) | 1.6 | $10M | NEW | 1.4M | 7.10 |
|
| Century Therapeutics (IPSC) | 1.6 | $10M | +68% | 4.1M | 2.45 |
|
| Inventiva Sa Ads (IVA) | 1.6 | $10M | 2.7M | 3.78 |
|
|
| Camp4 Therapeutics Corp (CAMP) | 1.3 | $8.4M | 1.9M | 4.37 |
|
|
| Altimmune Com New (ALT) | 1.3 | $8.1M | NEW | 2.7M | 3.04 |
|
| Minerva Neurosciences Com New (NERV) | 1.3 | $7.9M | 1.4M | 5.55 |
|
|
| Promis Neurosciences Com Shs (PMN) | 1.2 | $7.3M | 557k | 13.16 |
|
|
| Onkure Therapeutics Com Cl A (OKUR) | 1.0 | $6.6M | NEW | 1.4M | 4.56 |
|
| Forte Biosciences Com New (FBRX) | 0.9 | $5.8M | NEW | 273k | 21.25 |
|
| Research Alliance Corp Iii Ord Shs Cl A | 0.8 | $5.4M | NEW | 500k | 10.70 |
|
| Vtv Therapeutics Cl A New (VTVT) | 0.5 | $3.2M | -38% | 85k | 37.65 |
|
| Imagenebio (IMA) | 0.3 | $1.7M | NEW | 282k | 5.90 |
|
Past Filings by Trails Edge Capital Partners
SEC 13F filings are viewable for Trails Edge Capital Partners going back to 2026
- Trails Edge Capital Partners 2026 Q2 filed Aug. 14, 2026
- Trails Edge Capital Partners 2026 Q1 filed May 15, 2026